Robert Kamen

Dr. Robert Kamen is a consultant to the biotech and pharmaceutical industry. Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the U.S. (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and psoriasis, Humira was the most rapidly growing U.S. biological drug in 2007 and 2008. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. In addition, Dr. Kamen is a member of several other biopharmaceutical company boards.

Dr. Kamen has an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.